IBD HAS NO AGE is an EFCCA campaign started in 2022 in order to raise awareness of how Inflammatory Bowel Disease (IBD) is impacting on the life of people aged 60 years and over. This year, for World IBD Day 2023 (19 May), we will launch a survey on people with IBD aged 60 years and over to investigate more on this topic with questions related to both quality of care and quality of life.
The METHYLOMIC project will build on multiple previous cohort studies that confirmed epigenetic biomarkers (specifically DNA methylation) as the most stringent predictor of response to biological therapy, zooming in on CD. DNA methylation profiles in peripheral blood as biomarkers of response/deep remission for three approved biologicals in CD have been specifically discovered and validated.
The GlycanTrigger project proposes a thorough and innovative approach to understand better the health-to-chronic inflammation transition occurring in patients with CD that will be translated into improved disease prediction and prevention.
The GENEGUT project will transform the treatment of ileal CD by developing a first-in-class oral RNA-based therapy, tackling inflammation locally in the intestinal tissue, while avoiding systemic side effects.
EFCCA is involved in an exciting EU Research Project under the Innovative Medicines Initiative (IMI 2) (Horizon 2020).
The ImmUinverse project main goal is the improved diagnostic and therapeutic options for patients living with ulcerative colitis and atopic dermatitis. New insights into disease severity and progression will enable personalised therapy for each individual patient.
EFCCA is involved in this exciting project that will identify digital endpoints that provide reliable, objective and sensitive evaluation of activities of daily living and Health-related quality of life (HRQoL) in ImmuneMediated Inflammatory Diseases such as IBD as well as other such as Rheumatoid Arthritis and Lupus and which will ultimately have a positive impact on the quality of life of these patients.
Out‐of‐pocket expenses of patients with inflammatory bowel disease: a comparison of patient‐reported outcomes across 12 European countries
There is a high variability of out-of-packet patient costs of inflammatory bowel diseases (IBDs), but the issue is not widely recognised. Therefore, the study compared patient costs of IBDs between 12 European countries.
Transitioning through paediatric and into adult care is a critical time for patients and, if not carried out effectively and appropriately, can impact on education, mental health and patient outcomes. It has become clear that this is a major issue for patients, their carers and clinicians and that the transition process within and across Europe urgently needs reform.
The European Crohn’s and Colitis Organisation [ECCO] produces and regularly updates several guidelines to provide evidence-based guidance on critical aspects of IBD care to all health care professionals who manage patients with IBD.